As the U.S. stock market continues its rally, with the Dow Jones Industrial Average reaching record highs and the S&P 500 extending its winning streak, investors are increasingly exploring diverse opportunities across various sectors. Penny stocks, a term that may seem outdated but remains significant in investment circles, offer a unique blend of affordability and potential growth. Typically representing smaller or newer companies, these stocks can be attractive for those looking to uncover value in less-established firms with strong financials and promising prospects.
|
Name |
Share Price |
Market Cap |
Financial Health Rating |
|
BAB (OTCPK:BABB) |
$0.79 |
$6.1M |
★★★★★★ |
|
QuantaSing Group (NasdaqGM:QSG) |
$3.08 |
$143.12M |
★★★★★★ |
|
Golden Growers Cooperative (OTCPK:GGRO.U) |
$4.50 |
$69.71M |
★★★★★★ |
|
RLX Technology (NYSE:RLX) |
$1.83 |
$2.29B |
★★★★★★ |
|
ZTEST Electronics (OTCPK:ZTST.F) |
$0.2376 |
$8.57M |
★★★★★★ |
|
LexinFintech Holdings (NasdaqGS:LX) |
$3.40 |
$557.36M |
★★★★★★ |
|
Permianville Royalty Trust (NYSE:PVL) |
$1.55 |
$51.15M |
★★★★★★ |
|
Zynerba Pharmaceuticals (NasdaqCM:ZYNE) |
$1.30 |
$65.6M |
★★★★★☆ |
|
CBAK Energy Technology (NasdaqCM:CBAT) |
$0.8999 |
$80.04M |
★★★★★☆ |
|
Safe Bulkers (NYSE:SB) |
$4.08 |
$445.26M |
★★★★☆☆ |
Click here to see the full list of 720 stocks from our US Penny Stocks screener.
Let’s review some notable picks from our screened stocks.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: ProKidney Corp. is a clinical-stage biotechnology company focused on developing a proprietary cell therapy platform for treating chronic kidney diseases in the United States, with a market cap of $216.27 million.
Operations: ProKidney Corp. currently does not report any specific revenue segments.
Market Cap: $216.27M
ProKidney Corp., a clinical-stage biotechnology company, remains pre-revenue with less than US$1 million in revenue and faces ongoing financial challenges, evidenced by a net loss of US$17.91 million for Q3 2024. Despite this, the company has made strategic advancements in its Phase 3 trials for rilparencel, targeting advanced chronic kidney disease (CKD). The FDA’s confirmation of an accelerated approval pathway offers potential regulatory advantages. ProKidney’s cash reserves of US$430.2 million comfortably cover both short- and long-term liabilities and provide a runway into early 2027, although management and board experience are limited.
-
Unlock comprehensive insights into our analysis of ProKidney stock in this financial health report.
-
Examine ProKidney’s earnings growth report to understand how analysts expect it to perform.
Simply Wall St Financial Health Rating: ★★★★★☆
